Skip to main content
. Author manuscript; available in PMC: 2019 Apr 10.
Published in final edited form as: Nature. 2017 Nov 8;551(7680):389–393. doi: 10.1038/nature24484

Extended Data Figure 4. Functional interactions of the ASCC complex with other signaling pathways.

Extended Data Figure 4.

Immunofluorescence images of U2OS cells treated with MMS in the presence of spliceosomal inhibitor PLA-B (a) (100 nM; n=3 biological replicates; mean ± S.D.), the RNA Pol II inhibitor DRB (b) (100 μM; n=3 biological replicates; mean ± S.D.), or the indicated damage signaling kinase inhibitor (c) (n=2 biological replicates; mean). Numbers indicate the percent of cells expressing five or more ASCC3 foci. (d) Immunofluorescence of HA-ASCC2 and FK2 in cells after MMS (n=3 biological replicates; mean ± S.D.). (e) His-ASCC2 was purified on Ni-NTA, separated on a 10% SDS-PAGE gel, and analyzed by Coomassie blue staining (n=2 independent experiments). (f) Immunofluorescence of HA-ASCC2 cells and K63-ubiquitin (top) or K48-ubiquitin (bottom) after MMS treatment (n=2 independent experiments). Scale bars, 10 μm.